summari due report result wednesday juli
expect anoth strong quarter term
organ sale adj ep growth model sale
organ consensu adj ep
in-lin consensu wed note unclear
us street model updat reflect recent chang
fx rate refer guid organ growth
full-year guidanc adj ep
look respect busi expect
medic devic see anoth quarter strong growth albeit
modestli level ex-fx nutrit post
anoth quarter mid-single-digit growth epd establish
pharmaceut divis step back double-digit
rang behind easi y/i comp combin fundament
improv busi diagnost dx track
deliv guidanc roughli ex-fx ex-alr
altogeth would expect organ growth come least
in-lin organ estim fx becom
less favor sinc call would expect off-set
potenti impact bottom-lin full-year
given robust top-lin growth outlook still believ
like potenti upsid adj ep guidanc
despit fx move importantli continu believ
deliv top tier revenu ep growth next sever
chang estim larg due fx updat
estim incorpor recent chang fx rate
updat recent market model clear
continu believ strong fundament busi
remain intact fx account vast major chang
estim estim fx
tailwind sale respect
lower previou estim wrote
expect abl off-set potenti impact ep
continu believ ep upsid despit fx move
decreas sale estim
organ leav adj ep estim unchang
full-year lower sale estim
organ leav adj ep estim
unchang lower sale estim
report leav adj ep
estim unchang maintain price target
base adj ep estim
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort intang ep continu
oper ep includ stj amo alr deal
forecast includ stj acquisit alr deal amo divestitur
compani prioriti stock list
compani data secur llc estim reuter
expect nutrit growth mid-single-digit sens abt
nutrit busi post similar number guid
low mid-single-digit growth would expect growth fall somewher mid-singl digit
rangemean estim ex-fx like somewhat conserv base
convers manag china transit relat food safeti law continu go
expect continu robust devic growth similar recent quarter believ abt
devic busi bright spot guid mid high-singl digit devic growth
compar estim ex-fx look differ put take
devic expect continu mid high-teen neuromodul growth albeit tough comp
model ex-fx high-teen growth ep electrophysiolog behind legaci
busi confirm rx launch model ex-fx continu robust growth libr
model ww sale incl roughli flattish growth cardiac
rhythm manag model ex-fx soft lvad left ventricular assist
devic await destin therapi dt indic model ex-fx taken
altogeth would expect med devic growth modestli ex-fx solidli
high-single-digit rang
anticip bounc back epd epd sale growth deceler ex-fx
short abt epd guidanc high-single-digit shortfal primarili due
soft russia broader market growth slow due channel disrupt separ
also advers impact time dynam emerg market em countri
certain tender pull forward sale manag expect neg carryov
russia sens epd handili achiev guidanc double-digit growth
current model epd growth ex-fx believ like upsid estim
wed note analysi third parti data suggest improv growth abt india pharma
busi india account epd epd face particularli easi prior year compar
ex-fx relat implement gst good servic tax worth mention
epd tougher y/i comp ex-fx ex-fx said
sens manag feel confid achiev full-year epd guidanc high-single-digit
growth model ex-fx
diagnost growth like near guidanc base convers sens
diagnost dx growth like come around compani guidanc ex-fx ex-
alr model dx growth ex-fx ex-alr includ mid-single-digit growth
core lab point care poc low-single-digit growth molecular diagnost expect see
acceler dx growth behind on-going launch alin continu improv
molecular dx busi recal guid full-year dx growth ex-alr mid high-singl
price target nc
price target base ep estim risk target includ
slower growth key busi market delay stj alr integr slower margin
expect continu deliv double-digit underli ep growth mid-singl digit underli
sale growth oper leverag
abbott laboratori diversifi global medic product compani four key busi segment
nutrit diagnost establish pharmaceut epd medic devic compani report
total revenu compani acquir stj januari nearli doubl
 incom statement million except per share forma stj alr amo good sold fit fit includ includ med-tech fit fit includ expens fx loss expens ep continu ep includ discontinu analysiscost good margin margin fit fit compani report secur llc estim medic technolog
